A few targeted therapies have been approved, such as the checkpoint inhibitors pembrolizumab and nivolumab for recurrent or metastatic HNSCC, or the epidermal growth factor receptor (EGFR) inhibitor cetuximab for locally advanced HNSCC [14,15,16,17]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.